Patents Assigned to Molecular Design International
-
Patent number: 8912175Abstract: The invention provides a topical formulation adapted for treatment of a skin condition comprising (i) at least one retinoid; and (ii) salicylic acid or an ester, amide, salt, or solvate thereof. The invention also includes a kit for treatment of skin conditions comprising a retinoid and salicylic acid, as well as a method of treating skin conditions utilizing the inventive formulation and kit.Type: GrantFiled: September 18, 2014Date of Patent: December 16, 2014Assignee: Molecular Design International, Inc.Inventor: William P. Purcell
-
Patent number: 8865694Abstract: The invention provides a topical formulation adapted for treatment of a skin condition comprising (i) at least one retinoid; and (ii) salicylic acid or an ester, amide, salt, or solvate thereof. The invention also includes a kit for treatment of skin conditions comprising a retinoid and salicylic acid, as well as a method of treating skin conditions utilizing the inventive formulation and kit.Type: GrantFiled: May 3, 2013Date of Patent: October 21, 2014Assignee: Molecular Design International, Inc.Inventor: William Paul Purcell
-
Patent number: 7119103Abstract: The invention provides ?3-adrenoreceptor agonists, pharmaceutical compositions comprising ?3-adrenoreceptor agonist compounds, and methods of using such compounds for stimulating, regulating or modulating metabolism of fats in adipose tissue in animals.Type: GrantFiled: October 13, 2004Date of Patent: October 10, 2006Assignee: Molecular Design International, Inc.Inventors: Dennis R. Feller, Duane D. Miller
-
Patent number: 6919357Abstract: Aspects of the present invention are directed towards compounds of Formula I for the treatment of human erectile disorders including erectile dysfunction in men. wherein: R1 is hydrogen, halo, hydroxy, nitro, cyano, phenyl, trifluoromethyl, C1-C6 alkyl, C1-C6 alkoxy, carboxy, amino, cyclohexyl, C1-C6 alkylamino, or (C1-C6 alkyl)2amino; R2 is hydrogen, halo, hydroxy, nitro, cyano, trifluoromethyl, C1-C6 alkyl, C1-C6 alkoxy, carboxy, amino, C1-C6 alkylamino, or (C1-C6 alkyl)2amino; R3 is a group of the formula R4 is hydrogen or C1-C6 alkyl; R5 is hydrogen, halo, hydroxy, nitro, cyano, phenyl, trifluoromethyl, C1-C6 alkyl, C1-C6 alkoxy, carboxy, amino, C1-C6 alkylamino, or (C1-C6 alkyl)2amino; and R6 is hydrogen, halo, hydroxy, nitro, cyano, trifluoromethyl, C1-C6 alkyl, C1-C6 alkoxy, carboxy, amino, C1-C6 alkylamino, or (C1-C6 alkyl)2amino; or pharmaceutically acceptable salts thereof.Type: GrantFiled: August 9, 2002Date of Patent: July 19, 2005Assignee: Molecular Design International Inc.Inventors: Duane D. Miller, Seoung-Soo Hong
-
Patent number: 6825213Abstract: The invention provides &bgr;3-adrenoreceptor agonists, pharmaceutical compositions comprising &bgr;3-adrenoreceptor agonist compounds, and methods of using such compounds for stimulating, regulating or modulating metabolism of fats in adipose tissue in animals.Type: GrantFiled: June 25, 2003Date of Patent: November 30, 2004Assignee: Molecular Design International, Inc.Inventors: Dennis R. Feller, Duane D. Miller
-
Patent number: 6596734Abstract: The invention provides compounds of formula: wherein R1 is —NHS(O)mR, wherein R is alkyl, substituted alkyl, alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, or substituted heterocycle; X is independently selected from the group consisting of halo, alkyl, substituted alkyl, alkoxy, substituted alkoxy, hydroxy, nitro, amino, and substituted amino; R2 is benzyl or benzyl substituted with one or more substituents selected from the group consisting of halo, CF3, hydroxy, nitro, alkoxy, substituted alkoxy, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, amino, and substituted amino of formula —NHR' or —NR′R′, wherein each R′ is alkyl, substituted alkyl, —C(O)Y, —C(O)NHY, or —C(O)SY, wherein Y is alkyl or substituted alkyl; R3 is H or alkyl; nType: GrantFiled: October 11, 2002Date of Patent: July 22, 2003Assignee: Molecular Design International, Inc.Inventors: Dennis R. Feller, Duane D. Miller
-
Patent number: 6593341Abstract: The invention provides compounds useful as &bgr;3-adrenorecptor agonists and pharmaceutical compositions comprising such compounds. The invention further includes a method for stimulating, regulating, and modulating metabolism in fats of adipose tissue in mammals by administering an effective amount of a compound of the invention.Type: GrantFiled: June 17, 2002Date of Patent: July 15, 2003Assignee: Molecular Design International, Inc.Inventors: Dennis R. Feller, Duane D. Miller
-
Patent number: 5837728Abstract: Esters and amides of 9-cis-retinoic acid are synthesized, formulated into pharmaceutically acceptable carriers and administered for the treatment of acne vulgaris, cystic acne, hyper-pigmentation, hypo-pigmentation, psoriasis, dermal and epidermal hypoplasia and kerotoses, the reduction of wrinkling of the skin as an incident of aging and actinic damage, normalization of the production of sebum, the reduction of enlarged pores, promoting the rate of wound healing, limiting of scar tissue formation during healing and the like. They are additionally useful for treatment or amelioration of the same additional classes of skin disorders as is retinoic acid itself and other retinoids. These disorders include ichthyoses (e.g., ichthyosis hystrix, epidermolytic hyperkeratosis, and lamellar ichthyosis), follicular disorders (e.g., pseudofolliculites, senile comedones, nevus comidonicas, and trichostatis spinulosa), benign epithelial tumors (e.g.Type: GrantFiled: January 27, 1995Date of Patent: November 17, 1998Assignee: Molecular Design InternationalInventor: William P. Purcell
-
Patent number: 5124356Abstract: The dermal use of non-irritating retinoids such as the esters and amides of 13-cis and 13-trans-retinoic acid for effecting the reduction and reversal of photoaging and skin cancer is disclosed.Type: GrantFiled: November 6, 1990Date of Patent: June 23, 1992Assignee: Molecular Design International, Inc.Inventors: William P. Purcell, Harlie A. Parish, Jr.
-
Patent number: 5049584Abstract: The dermal use of non-irritating retinoids such as the esters and amides of 13-cis and 13-trans-retinoic acid for effecting the reduction and reversal of photoaging and skin cancer is disclosed.Type: GrantFiled: November 6, 1990Date of Patent: September 17, 1991Assignee: Molecular Design InternationalInventors: William P. Purcell, Harlie A. Parish, Jr.
-
Patent number: 4994491Abstract: The dermal use of non-irritating retinoids such as the esters and amides of 13-cis and 13-trans-retinoic acid for effecting the reduction and reversal of photoaging and skin cancer is disclosed.Type: GrantFiled: December 14, 1988Date of Patent: February 19, 1991Assignee: Molecular Design InternationalInventors: William P. Purcell, Harlie A. Parish, Jr.
-
Patent number: 4885311Abstract: Esters and amides of 13-trans-retinoic acid are disclosed which are used for the treatment of acne and skin diseases.Type: GrantFiled: June 29, 1987Date of Patent: December 5, 1989Assignee: Molecular Design InternationalInventors: Harlie A. Parish, William P. Purcell
-
Patent number: 4677120Abstract: Esters and amides of 13-cis-retinoic acid are disclosed which are used for the treatment of acne and skin diseases.Type: GrantFiled: July 31, 1985Date of Patent: June 30, 1987Assignee: Molecular Design InternationalInventors: Harlie A. Parish, William P. Purcell
-
Patent number: RE34075Abstract: The dermal use of non-irritating retinoids such as the esters and amides of 13-cis and 13-trans-retinoic acid for effecting the reduction and reversal of photoaging and skin cancer is disclosed.Type: GrantFiled: July 18, 1991Date of Patent: September 22, 1992Assignee: Molecular Design International, Inc.Inventors: William P. Purcell, Harlie A. Parish